CRBP - Corbus Pharmaceuticals Holdings, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Norwood,
United States
Type: Equity
CRBP price evolution
CRBP
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $13.11 | $26.44 | $57.7 | $25.68 |
| Short term investments | $53.79 | $47.53 | $29.09 | $72.64 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $67.35 | $75.24 | $88.48 | $100.2 |
| Long term investments | ||||
| Property, plant & equipment | $5.87 | $6.25 | $6.65 | $7 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.48 | $6.83 | $7.2 | $7.53 |
| Total investments | $53.79 | $47.53 | $29.09 | $72.64 |
| Total assets | $73.83 | $82.07 | $95.68 | $107.73 |
| Current liabilities | ||||
| Accounts payable | $1.37 | $1.99 | $2.7 | $1.78 |
| Deferred revenue | ||||
| Short long term debt | $11.13 | $8.79 | $6.79 | $5 |
| Total current liabilities | $17.47 | $15.63 | $15.12 | $17.01 |
| Long term debt | $14.39 | $16.94 | $19.38 | $21.59 |
| Total noncurrent liabilities | $14.42 | $16.97 | $19.4 | $21.61 |
| Total debt | $25.52 | $25.74 | $26.17 | $26.59 |
| Total liabilities | $31.88 | $32.6 | $34.52 | $38.62 |
| Shareholders' equity | ||||
| Retained earnings | -$381.2 | -$372.42 | -$359.17 | -$349.73 |
| Other shareholder equity | -$0.21 | -$0.12 | -$0.17 | -$0.06 |
| Total shareholder equity | $41.95 | $49.47 | $61.16 | $69.11 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $25.68 | $86.45 | $31.75 | $41.75 |
| Short term investments | $72.64 | |||
| Net receivables | $0.96 | $2.7 | ||
| Inventory | ||||
| Total current assets | $100.2 | $92.07 | $38.15 | $44.24 |
| Long term investments | ||||
| Property, plant & equipment | $7 | $9.32 | $10.9 | $2.71 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $7.53 | $10.22 | $10.99 | $2.75 |
| Total investments | $72.64 | |||
| Total assets | $107.73 | $102.29 | $49.14 | $46.99 |
| Current liabilities | ||||
| Accounts payable | $1.78 | $7.38 | $11.09 | $6.35 |
| Deferred revenue | $1.46 | |||
| Short long term debt | $5 | $1.71 | $1.35 | $0.39 |
| Total current liabilities | $17.01 | $31.9 | $34.89 | $18.09 |
| Long term debt | $21.59 | $25.12 | $8.1 | |
| Total noncurrent liabilities | $21.61 | $25.12 | $8.1 | $1.38 |
| Total debt | $26.59 | $26.84 | $9.45 | $0.39 |
| Total liabilities | $38.62 | $57.02 | $42.98 | $19.47 |
| Shareholders' equity | ||||
| Retained earnings | -$349.73 | -$304.09 | -$192.82 | -$121.37 |
| Other shareholder equity | -$0.06 | -$0 | ||
| Total shareholder equity | $69.11 | $45.27 | $6.16 | $27.52 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $4.11 | $2.5 | $3.29 | $5.76 |
| Selling, general & administrative | $4.07 | $4.84 | $5.23 | $4.23 |
| Total operating expenses | $8.18 | $12.34 | $8.52 | $10 |
| Operating income | -$8.18 | -$12.34 | -$8.52 | -$10 |
| Income from continuing operations | ||||
| EBIT | -$8.24 | -$12.76 | -$8.98 | -$9.87 |
| Income tax expense | ||||
| Interest expense | $0.54 | $0.49 | $0.46 | $0.39 |
| Net income | ||||
| Net income | -$8.78 | -$13.25 | -$9.44 | -$10.26 |
| Income (for common shares) | -$8.78 | -$13.25 | -$9.44 | -$10.26 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.88 | $3.94 | $36.14 | $4.82 |
| Cost of revenue | ||||
| Gross Profit | $0.88 | $3.94 | $36.14 | $4.82 |
| Operating activities | ||||
| Research & development | $36.45 | $98.27 | $89.6 | $48.61 |
| Selling, general & administrative | $20.43 | $28.48 | $23.64 | $12.96 |
| Total operating expenses | $56.87 | $126.75 | $113.25 | $61.57 |
| Operating income | -$55.99 | -$122.81 | -$77.1 | -$56.75 |
| Income from continuing operations | ||||
| EBIT | -$43.81 | -$110.24 | -$71.45 | -$55.67 |
| Income tax expense | ||||
| Interest expense | $1.83 | $1.03 | ||
| Net income | ||||
| Net income | -$45.64 | -$111.27 | -$71.45 | -$55.67 |
| Income (for common shares) | -$45.64 | -$111.27 | -$71.45 | -$55.67 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$8.78 | -$13.25 | -$9.44 | -$10.26 |
| Operating activities | ||||
| Depreciation | $0.37 | $0.37 | $0.37 | $0.38 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.35 | $1.51 | $1.59 | $1.79 |
| Total cash flows from operations | -$7.25 | -$12.23 | -$10.62 | -$9.7 |
| Investing activities | ||||
| Capital expenditures | $0.01 | -$0.01 | -$0.04 | |
| Investments | -$5.97 | -$18.7 | $42.98 | -$3.14 |
| Total cash flows from investing | -$5.97 | -$18.7 | $42.96 | -$3.18 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$0.11 | -$0.33 | -$0.33 | $0.77 |
| Total cash flows from financing | -$0.11 | -$0.33 | -$0.33 | $0.77 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$13.33 | -$31.26 | $32.02 | -$12.11 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$45.64 | -$111.27 | -$71.45 | -$55.67 |
| Operating activities | ||||
| Depreciation | $1.64 | $1.69 | $1.23 | $0.49 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.48 | $12.46 | $11.98 | $7.61 |
| Total cash flows from operations | -$48.18 | -$99.69 | -$45.72 | -$30.07 |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.48 | -$2.74 | -$2.3 |
| Investments | -$73.39 | |||
| Total cash flows from investing | -$73.42 | -$0.48 | -$2.74 | -$2.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $62.59 | $142.2 | $40.68 | $12.05 |
| Net borrowings | $0.06 | $18.71 | $0.36 | $0.06 |
| Total cash flows from financing | $60.82 | $154.87 | $38.46 | $11.42 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$60.78 | $54.7 | -$10 | -$20.95 |
News
Fundamentals
| Market cap | $858.17M |
|---|---|
| Enterprise value | $870.58M |
| Shares outstanding | 125.28M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$38.36M |
| EBIT | -$39.85M |
| Net Income | -$41.73M |
| Revenue Q/Q | -100.00% |
| Revenue Y/Y | -100.00% |
| P/E ratio | -20.57 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -22.70 |
| EV/EBIT | -21.85 |
| P/S ratio | N/A |
| P/B ratio | 20.36 |
| Book/Share | 0.34 |
| Cash/Share | 0.10 |
| EPS | -$0.33 |
|---|---|
| ROA | -46.46% |
| ROE | -75.30% |
| Debt/Equity | 0.56 |
|---|---|
| Net debt/EBITDA | -0.49 |
| Current ratio | 3.86 |
| Quick ratio | 3.86 |